Pharmaceuticals, Biotechnology and Life Sciences
Allergy Therapeutics, the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces its unaudited interim results for the six months ended 31 December 2016.
Alliance Pharma, the specialty pharmaceutical company, has announced results for the year ended 31 December 2016.
The Executive Board of Stada Arzneimittel AG has published the final figures for financial year 2016 which are, due to the revaluation of a transaction, diferent from the preliminary figures which the company had already published on March 1, 2017.
European Medicines Agency (EMA) has granted orphan designation to AstraZeneca’s and MedImmune’s inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
Guerbet, a global specialist in contrast agents and solutions for medical imaging, has published its consolidated and audited annual results for 2016.
Plasticell, a developer of stem cell technologies and cell-based therapies, has signed agreements with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.
Port Erin Biopharma Investments Limited has reported financial results for the six-month period ending 31 December 2016.
The Milner Therapeutics Institute is partnering up with Elysium Health to the Milner Therapeutics Consortium.
Xbrane Biopharma, a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long acting injectables, has delivered its first batch of Spherotide to its partner in the Middle East to a value of €0.7 million.
Sinclair Pharma has reported €18.8 million loss for 2016 which represents decrease comparing last years loss of €32.7 million.